rs104894226
|
|
|
0.710 |
GeneticVariation |
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
rs104894230
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
rs112445441
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Activating kinase alterations discovered in BRAF V600E-wildtype Langerhans (LCH) and non-Langerhans cell histiocytoses (non-LCH) result in constitutive activation of the mitogen-activated protein kinase and/or phosphoinositide 3-kinases-Akt murine thymoma pathways.
|
27101528 |
2016 |
rs121434569
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) amplification-induced phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog (AKT) activation and an EGFR T790M mutation, respectively, were used.
|
24698130 |
2014 |
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Activating kinase alterations discovered in BRAF V600E-wildtype Langerhans (LCH) and non-Langerhans cell histiocytoses (non-LCH) result in constitutive activation of the mitogen-activated protein kinase and/or phosphoinositide 3-kinases-Akt murine thymoma pathways.
|
27101528 |
2016 |
rs121913529
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
rs1222380251
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Activating kinase alterations discovered in BRAF V600E-wildtype Langerhans (LCH) and non-Langerhans cell histiocytoses (non-LCH) result in constitutive activation of the mitogen-activated protein kinase and/or phosphoinositide 3-kinases-Akt murine thymoma pathways.
|
27101528 |
2016 |
rs1569686
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study we investigated if a common polymorphism (-579G>T: rs1569686) in the promoter of the DNMT3B gene coding for the DNA methyltransferase 3B, an enzyme that mediates DNA methylation, increases the risk to develop MG or MG-associated thymomas.
|
24260492 |
2013 |
rs2476601
|
|
|
0.010 |
GeneticVariation |
BEFREE |
DNA samples from 416 patients with clinically diagnosed generalized MG (231 with Abs to acetylcholine receptor, AChR-MG), 53 with Abs to muscle-specific kinase (MuSK-MG), 55 patients with no detectable Abs (SN-MG), 77 patients with thymoma (TAMG) and 293 healthy controls (HC) were genotyped for the SNP (PTPN22 R620W, C1858T, rs2476601).
|
25119822 |
2014 |
rs727503094
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
rs77375493
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This activity was coupled with inhibition of phosphorylation of the key JAK2(V617F)-dependent downstream signaling effectors signal transducer and activator of transcription (STAT)3, STAT5, and v-akt murine thymoma viral oncogene homolog (AKT).
|
18482053 |
2008 |
rs104894226
|
|
A |
0.710 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs104894226
|
|
A |
0.710 |
GeneticVariation |
CLINVAR |
Thymic tumors: relevant molecular data in the clinic.
|
20859122 |
2010 |
rs1057519701
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
|
21325067 |
2011 |
rs1057519701
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
|
22357254 |
2012 |
rs1057519704
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
|
21969494 |
2011 |
rs1057519704
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
|
22357254 |
2012 |
rs1057519704
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
"When a thymic carcinoma ""becomes"" a GIST."
|
23375402 |
2013 |
rs1057519711
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
|
22357254 |
2012 |
rs1057519711
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
|
17699867 |
2007 |
rs1057519711
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
|
19461405 |
2009 |
rs121913235
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.
|
12960119 |
2003 |
rs121913235
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
|
22357254 |
2012 |
rs121913513
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
|
18448188 |
2008 |